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Diabetic nephropathy (DN) is the primary cause of morbidity
and mortality in patients with type 1 as well as type 2
diabetes, and accounts for 40% of end-stage renal disease in
the Western world. Familial clustering of DN suggests
importance of genetic factors in the development of the
disease. In the present study, we performed a two-stage
genome-wide scan to search for chromosomal loci containing
susceptibility genes for nephropathy in patients with type 1
diabetes. In total, 83 discordant sib pairs (DSPs), sibs
concordant for type 1 diabetes but discordant for
nephropathy, were collected from Finland, a homogeneous
population with one of the highest incidences of type 1
diabetes. To map loci for DN, we applied DSP analysis to
detect linkage. In the initial scan, 73 DSPs were typed using
900 markers with an average intermarker distance ofB4 cM.
Multipoint DSP analysis identified five chromosome regions
(3q, 4p, 9q, 16q, and 22p) with maximum logarithm of odds
(LOD) score (MLS) X1.0 (corresponding to a nominal P-value
p0.015). In the second stage, additional 43 markers flanking
these five loci were genotyped in all 83 DSPs. Using
simulations, we determined the empirical threshold with LOD
score of 1.76 and 3.12 for suggestive and significant linkage,
respectively. No locus reached the genome-wide significance
of 5%. However, one locus on 3q reached suggestive linkage
with MLS of 2.67 (P¼ 4.4 104). These results, together with
data from others, suggest that the locus on 3q most likely has
a susceptibility gene for DN.
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Nephropathy is a frequent complication of diabetes mellitus,
and the single most common disorder leading to end-stage
renal disease (ESRD). Diabetic nephropathy (DN) is the
primary cause of morbidity and mortality in patients with
type 1 diabetes mellitus (T1DM), and it also affects patients
with type 2 diabetes mellitus (T2DM).1 The changes in
kidney structure caused by diabetes are specific, with a
pattern not seen in other renal diseases. The kidney
complications manifest themselves first as microalbuminuria,
which then progresses to overt albuminuria, suggesting that
the renal filtration barrier, which consists of the glomerular
basement membrane and the podocyte slit diaphragm, is first
affected.1 The glomerular basement membrane gradually
becomes thicker and structurally disorganized, leading to
severe distortion of glomerular filtration. DN is frequently
associated with hypertension and often contributes to the
development of cardiovascular disease in type 1 diabetic
patients already at a relatively young age.2 Once overt
proteinuria has developed, progression to ESRD can be
retarded, but not prevented, by antihypertensive treatment
and careful glycemic control.
DN is believed to be a multifactorial disease caused by
both environmental and genetic factors. Duration of diabetes
and hyperglycemia are two of the strongest determinants of
DN.3 Other risk factors are hypertension, smoking and
hyperlipidemia.4,5 However, there is considerable evidence
showing that nephropathy is influenced by genetic factors,
particularly in T1DM.6–8 Although the proportion of ESRD
resulting from DN is high in T2DM, the kidney failure may
often be caused by non-diabetic factors, such as hypertension
or chronic infections. Epidemiologic studies have shown that
35% of patients with diabetes develop nephropathy irrespec-
tive of glycemic control,9,10 suggesting that a subgroup of
patients is at a high risk of developing nephropathy. The
incidence of nephropathy peaks during the second decade of
diabetes in T1DM subjects, and declines thereafter.10 Familial
clustering of nephropathy and ethnical variation have been
observed, regardless of the type of diabetes.3,8,9,11–14 The risk
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of developing DN to a second diabetic sibling within a family
is 71 or 25%, respectively, depending on whether the first
diabetic sibling has DN or not.14 In a recent Finnish
nationwide study, the estimated probability of progression
to DN by 20 years after onset of diabetes was 17% for the
siblings of the type 1 diabetic probands without DN, 38% for
the siblings of the probands with DN, and 41% for the
siblings of the probands with ESRD.7 The prevalence of DN is
especially high in Pima Indians, Nauruan, Asian Indians,
African-Americans, and Mexican-Americans.11,12,15,16 It is
not clearly known why there is an inter-racial difference in
the incidence of DN, but differences in genetic predisposition
might be a reason.
In this study, we describe a genome-wide linkage analysis
aimed at identifying DN susceptibility loci in Finnish
discordant sib pairs (DSPs) that are concordant for diabetes
but discordant for nephropathy,17 instead of the commonly
used affected sib pairs analysis. The main idea is to map loci
specifically for nephropathy in patients with T1DM, but not
for diabetes.
RESULTS
To search unbiased for genetic loci linked with DN, we
collected 73 families with type 1 diabetes, containing 83 DSPs
from Finland where the population is homogeneous and has
the highest incidence (B3%) of type 1 diabetes.18 The
clinical characteristics of the siblings are shown in Table 1.
Among 83 DSPs, DNA was available from 20 families with
two parents and 20 families with a single parent.
In the initial scan, 73 DSPs were typed with 900 markers
evenly distributed on the 22 autosomal chromosomes and the
X-chromosome. Successful typing data were obtained from
868 markers and the information content of the markers was
in average X70%. The initial genome scan results are
displayed in Figure 1. The most prominent linkage was
observed on chromosome 4p with a maximum logarithm of
odds (LOD) score (MLS) of 2.25 at 25 cM. The second
highest linkage with MLS of 1.71 at 143 cM was found on
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Figure 1 | Results of the initial genome-wide scan of 73 Finnish DSPs. LOD scores on the y axis are plotted against the genetic distance (cM)
on the x axis. Chromosome numbers are listed in each graph.
Table 1 | Clinical characteristics of 83 DSP included in the
study
DN+ siblings,
n=76
DN siblings,
n=79
Female/male (%) 41/59 51/49
Age at diabetes onset (years) 12.4478.22 (n=75) 17.65713.5 (n=76)
Duration of diabetes (years) 29.0777.84 (n=73) 25.4979.77 (n=70)
Blood pressure (mm Hg)
Mean systolic 139.49 (n=59) 132.64 (n=45)
Mean diastolic 79.8 (n=59) 81.22 (n=45)
ESRD (%) 16 —
Macroalbuminuria (%) 84 —
DN, diabetic nephropathy; DSP, discordant sib pairs; ESRD, end-stage renal disease;
n, number.
Data are means7s.d., % or n.
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chromosome 3q between D3S2496 at 126.83 cM and
D3S1565 at 186.04 cM. Interestingly, this region overlaps
with a region between 134.64 and 188.29 cM previously
reported linked with DN in Caucasian-Americans.19 The
other loci with MLS X1.0 (Po0.015) were identified on 16q
(MLS 1.44), 22p (MLS 1.37) and 9q (MLS 0.90). To exclude
potential marker typing errors or an error in the genetic map,
we also examined the ratio of observed/expected recombi-
nations in these five chromosomes. The ratio was 1.07 for
chromosome 3, 1.06 in chromosomes 4 and 9, whereas a
ratio of 1.16 and 1.23 was observed in chromosomes 16 and
22, respectively.
In the second stage, 10 more DSPs had been collected and
were included in the study. Additional 43 markers within
these five loci were genotyped in all 83 DSPs (Table 2). This
allowed the regions on chromosomes 3, 4, 9, 16, and 22 to be
typed at an average spacing of 2.6 cM. Chromosome 9q was
included in the second-stage analysis, as a linkage peak (MLS
0.9) in the Finnish families was observed in the flanking
region of a locus previously reported in Pima Indians.20 A
total of 22 markers (11 additional markers), spanning a
region of 64.13 cM (between 124.16 and 188.29 cM) with an
average intermarker distance of 2.9 cM on 3q, were analyzed
using an additive model (no assumption of dominance
variance). Multipoint linkage analysis increased the MLS on
3q to 2.24 (P¼ 6.6 104) at 149 cM (Figure 2). We also
analyzed this region using the multiplicative model (assump-
tion of dominance variance) and obtained significantly
improved LOD score (MLS 2.67, P¼ 4.4 104). The region
determined by the 1-LOD-unit support interval of the peak
on 3q is of 11 cM, between D3S3606 (143.16 cM) and
D3S3694 (154.16 cM). However, the peak extended over a
39-cM region between D3S1267 (139.12 cM) and D3S1614
(177.75 cM) with a nominal P-valueo0.05. The information
content within this 39-cM region was confirmed 485%. Our
most significant result in the initial scan came from
chromosome 4p (MLS 2.25), but after typing a higher
density of markers (13 additional markers), this region only
achieved an MLS of 0.87. Also, the MLS on 16q as well as on
22p decreased to 0.47 and 0.87, respectively. A slight increase
of MLS (at 141.42 cM) to 1.12 (P¼ 0.01) was found on 9q
(Figure 2).
Simulations were used to determine the empirical
genome-wide thresholds for suggestive and significant
linkage (i.e. the score that is exceeded once per genome scan
by chance or once per 20 scans at random). Under the null
hypothesis of no linkage, we generated random genotype
data matching our exact family structures, marker density,
and informativeness in the initial plus second-stage scan. In
1000 artificial genome scans, the threshold for suggestive and
significant linkage was determined to be MLS of 1.76 and
3.12, respectively. Using our simulation data, we observed
that only 340 of the 1000 simulated scans exceeded an LOD
score of 2.24 obtained by calculating under no assumptions
of dominance variance. This result indicates that in about a
third of genome-wide scans one would observe such LOD
score by chance. Therefore, our genome scan results reach the
criteria for genome-wide suggestive linkage (the score that
occurs once per genome scan by chance).
In power simulations, the 83 DSPs had 97% power to
detect significant linkage with LOD of 3.12 and almost 100%
power to find suggestive linkage with LOD of 1.76 using
multipoint linkage analysis under the assumption of full
penetrance. We also estimated power assuming incomplete
penetrance (90%), showing 66% power to find significant
linkage and 92% power to detect suggestive linkage.
DISCUSSION
This is the first study describing a genome-wide scan for
nephropathy susceptibility genes in T1DM. Importantly, by
using 900 tightly spaced markers followed by further
mapping of suggestive loci, this study yielded evidence for
suggestive linkage to a locus on 3q with MLS of 2.67 at
149 cM in the Finnish DSPs.
Most published genetic studies on DN have been based on
candidate gene studies. Many of these have shown conflicting
results without convincing conclusions. A genome scan has,
therefore, become a standard unbiased method searching for
linkage between genetic regions and phenotypes of interest.
Thus far, two complete genome scans for DN has been
reported, both performed in affected sib pairs with T2DM. In
the genome-wide scan for microvascular complications in
Table 2 | Summary of the second stage of linkage analysis in
totally 83 Finnish DSP
Chromosome
Size
(cM)
No of
additional
markers
genotyped
Total no.
of markers
analyzed
Average
spacing
(cM) MLS
3q 64 11 22 2.9 2.24
4p 46 13 21 2.2 0.87
9q 60 8 20 3 1.12
16q 48 7 19 2.7 0.47
22p 28 4 14 2 0.87
DSP, discordant sib pairs; MLS, maximum LOD score, calculated under no
assumption of dominance variance.
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Figure 2 | LOD scores on chromosomes 3 and 9 from first- and
second-stage analysis. The dashed line represents the LOD scores
from the initial genome-wide scan and the solid line represents
the LOD scores from the second-stage analysis. LOD scores on the
y axis are plotted against the genetic distance (cM) on the x axis.
Chromosome numbers are listed in each graph.
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Pima Indians, four loci with MLS 41.0 on chromosomes 3,
7, 9, and 20 were identified.20 The MLS of 1.48 on
chromosome 3 was at 181 cM, which is about 30 cM
telomeric to the region identified in this study. In one other
recent genome scan in African-Americans, evidence for
linkage was reported for chromosomes 3, 7, and 18.21 A
locus at 135 cM on 3q (LOD¼ 4.55), that is, slightly
centromeric to the Finnish locus, was observed by using
ordered subset analysis. In a candidate gene study of type 1
diabetic nephropathy, Moczulski et al.19 reported linkage of
DN in Caucasian-Americans to a 63-cM region (MLS 3.1
approximately at 165 cM) on 3q, which places the LOD peak
in between the locus identified in this study and the Pima
Indian study. Since this 3q-locus now has been replicated in
four independent populations using an identical allele
sharing analysis method in siblings, it is most likely to
include a true DN susceptibility gene. The AGTR1 gene, an
interesting candidate gene lies in the 39-cM region mapped
in this study. However, after the region was further fine-
mapped using association analysis of a large case–control
material, no association was found in the Finnish population
(unpublished data).
The precise position of the peaks on 3q (135 cM in
African-Americans, 149 cM in Finns, 165 cM in Caucasian-
Americans and 181 cM in Pima Indians) varies in the four
studies. The distance between the peaks in the African-
American study and the Finnish study is about 14 cM. While
a proximate 16-cM gap between peaks of MLS from the
Caucasian-American and the Finnish studies is found. In fact,
our broad 39-cM region between markers with a nominal
Po0.05 fully overlaps the critical interval of the Caucasian-
American linkage studies, providing further support to the
suggestion that this might be a true positive result.22 Slightly
different location of LOD score peaks is often observed in
replicate studies and it might also reflect complexity of the
phenotype, such as ethnical heterogeneity, variable diagnostic
criteria, etc. However, the precision of genome scans for
complex traits might also influence the location of the peak
observed. This 3q-locus mapped by four independent studies
might be prone to nephropathy under the status of
hyperglycemia, regardless of type of diabetes, as in the
studies of Pima Indians and African-Americans, patients with
type 2 diabetic nephropathy were investigated. Interestingly, a
B60-cM mouse region on 3q, syntenic to human chromo-
some 3q25–27, showed highly significant linkage (LOD score
4.9 at D3Mit203) to HIV-1-associated nephropathy,23
suggesting that this locus may be prone to many forms of
kidney diseases.
In the study of the Pima Indians, chromosome 9 showed a
weak linkage with both nephropathy and retinopathy.20 The
locus on 9q identified in the Finns, telomeric of the Pima
locus, did however, not reach significance after analysis with
additional more dense markers. This genetic region has not
been confirmed in any other population. DN candidate genes
angiotensin-converting enzyme on 17q23,24 SLC12A3 on
16q13,25 and CNDP1 on 18q22.3–2326 have previously been
associated with nephropathy in cases and controls, but this
study did not reveal linkage in Finnish DN patients, although
the marker information content was 71, 70, and 76%,
respectively.
If affected sib pairs are used in this study, loci detected are
most likely responsible for both diabetes and nephropathy,
and no doubt, the HLA locus on 6p21 will show the highest
peak. Risch and Zhang27 showed that extremely DSPs, one in
the top 10% and the other in the bottom 10% of the trait
distribution, provide substantial power for mapping quanti-
tative trait loci, such as those contributing to hypertension
and obesity. Later, Rogus and Krolewski17 showed that DSP
analysis is highly powerful for mapping qualitative trait loci if
a sibling has a high recurrence risk. They proposed that DSPs
are preferable for the analysis of DN due to a 70% of
recurrence risk among siblings with type 1 diabetes. The
power of DSPs is, however, profoundly impacted by reduced
penetrance, that is, an unaffected sibling is actually a non-
penetrant disease–allele carrier. In present study, the 15-year
normoalbuminuria criteria can, to great extent, minimize the
impact, but the criteria may have resulted in inclusion of
siblings at future risk of nephropathy. This may dilute the
power of the DSP strategy.
DSP families collected from Finland might benefit our
mapping result. First, Finland represents an ideal population
for mapping and cloning Mendelian disease genes, because of
its isolation, founder effect28 and good medical care system,
although its advantage for common diseases still needs to be
proven.29 Second, Finland has one of the highest incidences
of T1DM in the world,18,30 which allowed us to recruit
enough well-characterized sib pairs with type 1 diabetes from
the whole country. Childhood-onset type 1 diabetes accounts
for only 5–10% of total diabetes; nevertheless, for study of
genetics of diabetes, confounding factors may be of lesser
concern compared with later-onset type 2 diabetes. Environ-
mental risk factors such as obesity, smoking, hypertension,
diet, and so on may interact frequently with diabetes
susceptibility genes in the development of type 2 diabetes.31
To some extent, it can result in unexpected results for the
genetic analysis.
In conclusion, well-characterized DSPs, a highly dense
marker map and a well-established multipoint DSP linkage
analysis, allowed us to obtain evidence for a susceptibility
locus on 3q for DN. Based on the material (83 DSPs) from
Finland, our results in the 3q region satisfy criteria of
genome-wide suggestive linkage. Together with previously
published data,19–21 this 3q locus most likely harbors a
susceptibility gene for DN and deserves further study.
MATERIALS AND METHODS
Families
DSP families were ascertained from the Finnish nationwide hospital
discharge registry database with hospital discharge before 1996 and
from the nationwide Finnish diabetes registry.18 Nephropathy cases
were identified among patients who had had T1DM for at least 10
years with age of onset 20 years or younger. Family information was
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obtained from several sources: (i) questionnaires sent to the
patients, and if they stated that they had a diabetic sibling who
gave a permission to be contacted, he/she was then sent information
about the study and the questionnaire; (ii) through the computer-
ized record linkage to the national hospital discharge registry using
the unique personal identification number assigned to all Finnish
residents; and (iii) through the record linkage to the nationwide
diabetes registry located at the National Public Health Institute. If a
sibling with T1DM was identified, the family was included in the
study to search for DSPs. Urine samples and patient records were
collected to assess for the presence or absence of nephropathy
diagnosis (see below). In this manner, we obtained a total of 460
families with at least two T1DM affected sibs. From these 460
families, 73 DSP families (83 DSP pairs) with and without urine
and/or medical record confirming nephropathy diagnosis were
eligible for the present family study. Blood samples for DNA
extraction, sera for biochemical assays, and urine for albumin and
creatinine excretion measurements were obtained from the study
subjects. Also, blood was collected from parents who agreed to
participate.
The study subjects gave an informed consent, and the study was
approved by the Ethical Committees of the Finnish National Public
Health Institute and the Karolinska Institute.
Nephropathy diagnosis
Urinary albumin excretion rate (UAER) or urinary albumin/
creatinine ratio (ACR) and review of medical records were primarily
used to define the nephropathy phenotype. T1DM individuals were
considered free of nephropathy if their urinary albumin levels
remained normal UAER was o20 mg/min or ACR o2.5 mg/mmol)
after at least 15 years of diabetes. There were 79 such unaffected
siblings (DN siblings) in the study, with mean duration of diabetes
of 25 years and no indication of nephropathy in the medical records
(Table 1). The T1DM individuals with macroalbuminuria UAER
4200mg/min or ACR X25 mg/mmol) or ESRD were diagnosed as
nephropathy. Totally 76 patients were classified as DNþ siblings,
84% had macroalbuminuria and 16% had ESRD (Table 1).
Individuals with microalbuminuria UAER 20–200mg/min or ACR
2.5–25 mg/mmol) were excluded from the study. Similarly,
all microalbuminuric individuals who had previously obtained
angiotensin-converting enzyme inhibitor or angiotensin receptor
blocker treatment and turned normoalbuminuric were excluded
from the study.
Many of the individuals with nephropathy had retinopathy, but
genetic linkage to this phenotype was not part of this study.
Genotyping
DNA was extracted from peripheral lymphocytes, according to
standard procedures. In the initial stage, a genome-wide scan was
performed using 900 microsatellite markers as described pre-
viously.32 Information of the microsatellite markers was obtained
from the Marshfield genetic map (http://www2.marshfieldclinic.org/
RESEARCH/GENETICS/Map_Markers/maps/IndexMapFrames.html).
In the marker set used in this study, the average spacing between
markers was B4 cM, with no gaps 410 cM. Standard PCR
techniques with fluorescently labelled primers were used to amplify
polymorphic DNA fragments. The PCR products were supplemen-
ted with internal size standards, separated, and detected on an
Applied Biosystems model 377 sequencer by use of Genescan version
3.0 peak-calling software. Alleles were called automatically with the
TrueAllele program (Cybergenetics, http://www.cybgen.com), and
the DecodeGT program was used to fractionate according to quality
and to edit the called genotypes.33
In the second stage, additional 43 markers were genotyped in loci
with LOD score X1.0.
Statistical analysis
The complete data set was screened for Mendelian inconsistencies by
the ASPEX package (version 2.3). Inconsistencies were removed
from the analysis. We assessed observed versus expected recombina-
tions for detecting double recombinations and other more subtle
data errors by use of the GENEHUNTER program (version 2.0).34
DSPs, sibs affected with T1DM but discordant for nephropathy,
were used to map DN loci, as described previously.17 For DSP
analysis, the exact same procedure as for affected sib pair analysis
can be performed to calculate the MLS. Linked markers will be
characterized by diminished, as opposed to excessive, allele sharing
between sibs, but significant deviations from null values will still be
detected by the MLS, as it is based on the likelihood ratio.17 An
allele-sharing method was used in the analyses to assess evidence for
linkage. All genotyping data were analyzed using the ASPEX
program. We also used a modified version of MAPMAKER/SIBS
(kindly provided by John Rogus),35 where the status of DSPs
allowed for testing, to verify results. Allele frequencies were
estimated from whole pedigrees. To avoid non-independence of
sib pairs in multiple sibships, we used only the first n1 sib pairs
from sibships of size n. In the initial scan, we performed linkage
analyses under no assumptions of dominance variance, by fixing the
one allele sharing proportion (z1) at 1/2, thereby reducing the
number of free parameters to one. Consequently, P-values for the
full analysis are based on 1 degree of freedom. In this model, it is
assumed that the genetic component of trait’s phenotypic variances
is due to additive effects of genes at different loci and the model
approximates genetic heterogeneity and allows for no interaction
between loci.36 In the second stage, we genotyped additional
markers in loci with MLS X1.0 and conducted data calculations,
using both no assumptions and assumption of dominance variance
(possible triangle method), which follows a multiplicative model.
The possible triangle method represents epistasis (interaction)
among loci and has been shown to increase power of the
likelihood-ratio test.37 To ensure that the linkage result was a true
reflection of the information contained in the material, the
information content in the region of interest was X85%. By use
of an information content based on the variance of the identical by
descent distribution, we can obtain a correct measure of the amount
of identical by descent information extracted.35
Computer simulations
To estimate the genome-wide significance level of our scan results,
we also performed simulations under the null hypothesis of no
linkage. We used the SIMULATE program (version 2.5)38 to
generate random genotype data for simulations. By accounting for
the particular nature of our data set, we used our real data, such as
number of families with identical structures, the scan marker map
used in two stages, and marker informativeness as simulation
parameters. We generated 1000 artificial genome scans (23 000
chromosomes) and the data was analyzed by using the ASPEX
program under no assumptions of dominance variance. Genome-
wide scan significance level is defined as the probability that one
would encounter a deviation somewhere in the whole-genome scan.
The threshold of LOD scores for suggestive or significant linkage is
therefore once or 0.05 times per genome scan, respectively.39
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To estimate power of the DSPs collected to detect linkage, we
used the simulation program, SLINK,40 to generate 1000 replicates
of the 83 DSPs with real family structures using two linked marker
loci with the interval of 5 cM, assuming a dominant model with
complete or incomplete penetrance, no phenocopies, and 70% PIC
for markers. Simulated genotype data were analyzed by using the
ASPEX program with z1¼ 1/2.
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